← Back to Clinical Trials
Recruiting Phase 2, Phase 3 NCT05181748

Autologous Platelet Rich Plasma Intraovarian Infusion for Poor Responders

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Poor Response to Ovulation Induction
Sponsor Genesis Athens Clinic
Study Type INTERVENTIONAL
Phase Phase 2, Phase 3
Enrollment 100
Sex FEMALE
Min Age 35 Years
Max Age 47 Years
Start Date 2019-01-23
Completion 2025-12-31
Interventions
Autologous platelet rich plasma

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Autologous platelet rich plasma (PRP) intraovarian infusion may improve ovarian response to controlled ovarian stimulation as well as the hormonal profile of poor ovarian response infertile women subjected to intracytoplasmic sperm injection (ICSI) treatment.

Eligibility Criteria

Inclusion Criteria: Poor Ovarian Response according to Bologna Criteria (fulfilling 2 out of 3 of the following): 1. Age ≥ 40 years 2. AMH \< 1.1 ng/ml OR AFC \< 7 3. ≤ 3 oocytes with a conventional stimulation protocol * Discontinuation of any complementary/adjuvant treatment including hormone replacement and acupuncture, for at least three months prior to recruitment. * Willing to comply with study requirements Exclusion Criteria: * Any pathological disorder related to reproductive system anatomy * Cycle irregularities * Amenorrhea * Endometriosis * Adenomyosis * Fibroids and adhesions * Infections in reproductive system * Current or previous diagnosis of cancer in reproductive system * History of familiar cancer in reproductive system * Severe male factor infertility * Prior referral for Preimplantation Genetic Testing (PGT) -Ovarian inaccessibility -Endocrinological disorders (Hypothalamus- * Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome) * BMI\>30

Related Trials

}
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology